AUVEN THERAPEUTICS
Auven Therapeutics is a private equity company focused on the healthcare industry. The Companyโs strategy is to acquire controlling ownership in promising therapeutic products or platforms. The value of these therapeutic assets is then significantly enhanced by global development programs prior to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics has built a diversified portfolio of biologic and small molecule therape... utic candidates for a wide range of therapeutic indications. The Companyโs existing pipeline addresses critical unmet medical needs in cancer, ophthalmic conditions, womenโs health and orphan diseases. It has ownership of or a controlling interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals. Founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda. Auven Therapeutics is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Management L.L.L.P. Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda.
AUVEN THERAPEUTICS
Social Links:
Industry:
Advice Health Care Therapeutics
Founded:
2007-01-01
Address:
Delray Beach, Florida, United States
Country:
United States
Website Url:
http://www.auventx.com
Total Employee:
101+
Status:
Active
Contact:
(340) 779-6908
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Domain Not Resolving Apache
Similar Organizations
Lannett Company
Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Montes Archimedes Acquisition Corp
Montes Archimedes Acquisition Corp is a Special Purpose Acquisition Company with a focus on the health care industry.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Current Employees Featured
Founder
Investors List
PPD
PPD investment in Funding Round - Auven Therapeutics
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2019-06-12 | ADC Therapeutics | Auven Therapeutics investment in Series E - ADC Therapeutics | 76 M CHF |
2017-10-23 | ADC Therapeutics | Auven Therapeutics investment in Series E - ADC Therapeutics | 200 M USD |
2016-10-27 | ADC Therapeutics | Auven Therapeutics investment in Series D - ADC Therapeutics | 105 M USD |
2015-09-02 | ADC Therapeutics | Auven Therapeutics investment in Series C - ADC Therapeutics | 80 M USD |
2013-10-16 | ADC Therapeutics | Auven Therapeutics investment in Series B - ADC Therapeutics | 40 M USD |
2012-03-26 | ADC Therapeutics | Auven Therapeutics investment in Series A - ADC Therapeutics | 50 M USD |
2010-01-20 | Kolltan Pharmaceuticals | Auven Therapeutics investment in Series B - Kolltan Pharmaceuticals | 10 M USD |
2009-10-22 | Spirogen | Auven Therapeutics investment in Private Equity Round - Spirogen | 15 M USD |
2009-10-12 | Kolltan Pharmaceuticals | Auven Therapeutics investment in Series A - Kolltan Pharmaceuticals | 5 M USD |
2008-07-31 | Kolltan Pharmaceuticals | Auven Therapeutics investment in Series A - Kolltan Pharmaceuticals | 40 M USD |